Clinical Trial Update: A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) [Phase 2]

View source ↗

Summary

Phase 2 trial in chemotherapy‑naïve metastatic castration-resistant prostate cancer comparing AT-101 plus docetaxel and prednisone versus docetaxel and predniso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• AT-101 (gossypol acetic acid)
• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Ascenta Therapeutics | Conditions: Hormone Refractory Prostate Cancer | Phase 2 | Status: COMPLETED